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Non-human primatesIn wild-type human parainﬂuenza virus type 2 (WT HPIV2), one gene (the P/V gene) encodes both the
polymerase-associated phosphoprotein (P) and the accessory V protein. We generated a HPIV2 virus
(rHPIV2-Vko) in which the P/V gene encodes only the P protein to examine the role of V in replication in vivo
and as a potential live attenuated virus vaccine. Preventing expression of V protein severely impaired virus
recovery from cDNA and growth in vitro, particularly in IFN-competent cells. rHPIV2-Vko, unlike WT HPIV2,
strongly induced IFN-β and permitted IFN signaling, leading to establishment of a robust antiviral state.
rHPIV2-Vko infection induced extensive syncytia and cytopathicity that was due to both apoptosis and
necrosis. Replication of rHPIV2-Vko was highly restricted in the respiratory tract of African green monkeys
and in differentiated primary human airway epithelial (HAE) cultures, suggesting that V protein is essential
for efﬁcient replication of HPIV2 in organized epithelial cells and that rHPIV2-Vko is over-attenuated for use
as a live attenuated vaccine.
Published by Elsevier Inc.Introduction
Human parainﬂuenza virus serotypes 1, 2 and 3 (HPIV1-3) are
negative-stranded, non-segmented, enveloped RNA viruses that
belong to the Paramyxoviridae family. These HPIVs are a major
cause of respiratory illness in children and account for 18% of pediatric
hospitalizations for acute respiratory tract infection (Murphy, 1988).
HPIV disease ranges from mild upper respiratory tract illness (URTI)
to severe lower respiratory tract disease, including croup, bronchio-
litis and pneumonia. HPIV2 is thought to be an important cause of
URTI, croup, and undifferentiated febrile illness (Kapikian et al., 1963;
Parrott et al., 1962). Currently, there are no effective antiviral
therapies or vaccines to treat or prevent HPIV infections.
Unlike HPIV1 and HPIV3, which are both members of the genus
Respirovirus, HPIV2 is a Rubulavirus. It encodes 7 polypeptides from
6 genes arranged in the order 3′-N-P/V-M-F-HN-L-5′. The HPIV2
genome is 15,654 nucleotides in length and requires a genome
nucleotide length that is a multiple of six for efﬁcient replication
(known as the “rule of six”) (Skiadopoulos et al., 2003). Transcription
and replication are directed by the viral nucleocapsid protein (N), theive, Bldg. 50, Room 6515, MSC
1268.
utt).
Inc.phosphoprotein (P), and the large polymerase (L) protein (Karron and
Collins, 2007). The fusion (F) and hemagglutinin-neuraminidase (HN)
glycoproteins are the major protective antigens for the HPIVs and are
associated with the viral envelope, along with the internal matrix
protein (M) (Murphy, 1988). The remaining polypeptide, the
accessory V protein, has been identiﬁed as an antagonist of the type
I interferon (IFN) response (Andrejeva et al., 2004; He et al., 2002;
Horvath, 2004; Poole et al., 2002; Young et al., 2000).
The P/V gene of HPIV2 encodes both the phosphoprotein P subunit
of the viral polymerase and the accessory V protein (Ohgimoto et al.,
1990). Unedited transcription of the P/V gene yields an mRNA that
codes for the V protein. Alternatively, the co-transcriptional insertion
of two non-templated guanine nucleotides by RNA editing generates
an mRNA with a frame shift that codes for the P protein. Therefore, P
and V proteins share the ﬁrst 164 N-terminal amino acids but have
distinct C-termini. RNA editing to insert pseudotemplated G nucleo-
tides is a conserved viral mechanism that occurs in nearly all members
of the ﬁve genera in subfamily Paramyxovirinae (Karron and Collins,
2007).
The P protein is an essential component of the viral RNA
polymerase with multiple roles in mRNA transcription and genome
replication (Lamb and Parks, 2007). The primary function of the V
protein appears to be inhibition of the innate antiviral response,
though V is also believed to play a part in preventing apoptosis and
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Lin and Lamb, 2000; Poole et al., 2002; Wansley and Parks, 2002). The
latter function may be mediated through binding of the V protein to
the virus N and L proteins as well as to RNA (Lin et al., 1997; Nishio et
al., 2008, 2007, 2006; Randall and Bermingham, 1996). In addition to
these functions, the V proteins of rubulaviruses are components of the
virions, whereas V has not been detected in the virions of
respiroviruses or morbilliviruses (Curran et al., 1991; Paterson et al.,
1995). A role for V in virion morphogenesis has been suggested but
remains to be deﬁned in detail (Kawano et al., 2001).
The innate immune response is a powerful host defense against
virus infection and, as a result, is a target for interference by proteins
encoded by many diverse viruses (Fensterl and Sen, 2009; Goodbourn
et al., 2000). RNA virus infection is detected by a number of host cell
pathogen recognition receptors (PRRs) that induce innate immune
responses such as the IFN and apoptotic responses. Toll-like receptors,
which are expressed on the cell surface and in endosomes, recognize
speciﬁc viral products such as viral nucleic acids present in
intracellular vesicles or in the extracellular environment, whereas
retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-
associated gene 5 (MDA5) are constitutively expressed RNA helicases
that detect viral RNAs in the cytosol. Activation of either type of PRR
signals both IFN-α/β synthesis and subsequent IFN-α/β signaling
through its receptor (Koyama et al., 2007; Yoneyama and Fujita, 2007;
Yoneyama et al., 2004). IFNs are secreted from most cells and can act
in either an autocrine or paracrine manner. The effects of IFN on the
host cell are initiated by engagement and multimerization of the IFN-
α-receptor (IFNAR) by IFN-α or IFN-β. The IFNAR-associated tyrosine
kinases, Tyk2 and Jak1, phosphorylate IFNAR1 and 2 receptor
subunits, thereby triggering recruitment, phosphorylation and release
of STAT1 and STAT2 from the receptor into the cytoplasm. Activated
STAT1 and STAT2 associate with IRF9 to form a complex known as
interferon-stimulated gene factor 3 (ISGF3), which translocates to the
nucleus and activates transcription of IFN-inducible genes (ISGs). The
ISGs establish an antiviral state in both infected and uninfected cells
and also serve to augment the adaptive immune response (Fensterl
and Sen, 2009).
One attractive strategy that has been proposed for attenuating
viruses for use as live virus vaccines involves deleting or mutating IFN
antagonists encoded by viruses (Talon et al., 2000). The multifunc-
tional V protein of HPIV2 has been shown to counteract the IFN
response at two steps: limiting induction of IFN biosynthesis by viral
dsRNA through an interaction with the RNA helicase MDA5
(Andrejeva et al., 2004; Childs et al., 2007) and blocking IFN signaling
by engaging STAT1 and STAT2 proteins in a cytoplasmic complex with
a cellular E3 ubiquitin ligase, resulting in ubiquitination and
proteasomal degradation of STAT2 (Andrejeva et al., 2002; Nishio et
al., 2002, 2005). These data suggest that mutation or ablation of HPIV2
V protein could be used as a strategy to generate a live attenuated
HPIV2 vaccine candidate. However, as potential complications,
abrogation of the IFN-independent function of V on polymerase
activity and replication by mutation could result in a reduction in the
yield of live vaccine in cell culture during manufacture or in over-
attenuation of the vaccine in vivo.
Previously, two recombinant HPIV2 viruses, one with mutations
preventing V protein expression entirely and one with mutations
creating a V protein with a truncated C-terminal domain, were
derived from the Toshiba strain of HPIV2 (Kawano et al., 2001; Nishio
et al., 2005). Both mutants were highly restricted for replication in a
number of cell lines, including in Vero cells, which cannot produce
type I IFNs (Kawano et al., 2001; Nishio et al., 2005). However, the
efﬁciency of growth of these two V mutants in vivo was not reported,
and the full genome sequencewas not presented. In the present study,
we used a rule-of-six-compliant recovery system to generate an
independent recombinant HPIV2 (rHPIV2-Vko) in which V expression
was ablated by the introduction of alterations in the RNA editing siteof the P/V gene, similar to the HPIV2 mutant generated by Nishio
et al. (2005). Sequence analysis of recovered rHPIV2-Vko virus
conﬁrmed that it had a wild-type sequence in all expressed proteins
(Skiadopoulos et al., 2003) and that rHPIV2-Vko contained only one
incidental mutation in a noncoding region judged to be biologically
insigniﬁcant. This study extends the previous observations by
examining the ability of rHPIV2-Vko to induce the synthesis of IFN,
to inhibit IFN signaling through its receptor, to replicate in vivo in
non-human primates, and to replicate in human well-differentiated
primary airway epithelial cells in culture. rHPIV2-Vko was found to be
restricted for growth in vitro due to enhanced cytopathic effect (CPE)
and an inability to antagonize both the induction of IFN and IFN
signaling through its receptor. These defects proved to be highly
restrictive for growth in African green monkeys (AGMs) and in
cultures of human ciliated airway epithelium (HAE).
Results
Construction and recovery of rHPIV2 that does not express V protein
In wild-type (WT) HPIV2, the P and V mRNAs are encoded by
overlapping reading frames, as illustrated in Fig. 1A. HPIV2 and other
paramyxoviruses use a unique mechanism of mRNA editing to insert
pseudotemplated G residues during transcription of the P gene. Upon
reading a speciﬁc editing site (depicted in Fig. 1A), the viral
polymerase occasionally “stutters,” slippage of the nascent mRNA
occurs, and one or more extra G nucleotides are added. In P genes
from genus Respiro-, Avula-, Henipa- and Morbillivirus, the unedited
mRNA encodes P, while insertion of one G residue produces V mRNA.
The opposite occurs in the Rubulaviruses, where the unedited mRNA
encodes V and the edited version encodes P via a two-nucleotide
frame shift (Fig. 1A). Other groups have previously demonstrated that
it is possible to prevent HPIV2 V protein expression by mutating the
RNA editing site in the P/V gene (Kawano et al., 2001; Nishio et al.,
2005). Using our reverse genetics system that is based on the
sequence of a low passage HPIV2 clinical isolate that replicates to high
titer in non-human primates (Nolan et al., 2007), we altered the P/V
editing site to create the two-nucleotide frame shift, so that the
unedited mRNA encodes only P, and disrupted the string of G
nucleotides by substitution mutagenesis in order to inactivate editing
(Fig. 1B). This was done without introducing any coding mutations
into P.
We observed that this recombinant virus (rHPIV2-Vko) had a lower
frequency of recovery from cDNA than rHPIV2-WT in IFN-competent
HEp-2 cells. rHPIV2-Vko was recovered in 5 out of 12 transfections
(42% recovery rate) whereas rHPIV2-WT was recovered in all 12
transfections (100% recovery). One of the ﬁve recovered rHPIV2-Vko
populations had an editing site that was restored exactly to that of the
WT virus, though other introduced sequence changes (e.g., restriction
sites) were present in the sequence of the recovered virus (Table 1,
mutant 5). Another mutant (Table 1, mutant 4) had an editing site
that was restored to that of the WT virus except that it was three G
residues longer; thus, its P editing site had gained a single nucleotide
in length compared with the original Vko mutant sequence, and this
gain appeared to be compensated for by a single-nucleotide deletion
in the poly(A) tract at the end of the N gene-end signal (Table 1,
mutant 4). A third mutant had ten T to C mutations between the open
reading frames of N and P that highly impaired its growth in vitro
(Table 1, mutant 3). The ﬁnal two recovered rHPIV2-Vko isolates had P
editing sites that retained all of the mutations of the original Vko
mutant, although both contained a single, different nucleotide
substitution in the gene-end signal of the N gene (Table 1, mutants
1 and 2). Mutant 2 contained a T to A substitution at nucleotide (nt)
1912 in the N gene-end signal, whose phenotypic consequences were
not investigated. The N gene-end region was a site of adventitious
mutations in 4 of the 5 recovered rHPIV2-Vko isolates and is therefore
Fig. 1. Generation of rHPIV2 that does not express the V protein. (A) Schematic representation of the wild-type (WT) HPIV2 genome. The nucleotide sequence at the P/V mRNA
editing site is shown for both the P and V mRNAs with underlined nucleotides denoting the sites of seven (V mRNA) or nine (P mRNA) G residues. As indicated, the P and V proteins
share identical N-terminal sequences but have unique C-terminal sequences after the editing site. (B) Diagram of HPIV2 cDNA used to recover infectious rHPIV2-Vko. The unique,
silent restriction enzyme sites AscI, BstEII, AgeI, and SacII were introduced in order to alter the editing site in the P gene. The nucleotide sequence of the mRNA editing site in the P
ORF is shown with the three nucleotide substitutions introduced to disable the editing site presented in bold. (C) Expression of HPIV2 proteins in LLC-MK2 cells mock-infected or
infected with rHPIV2-WT or rHPIV2-Vko. Cells were infected at an MOI of 5.0 TCID50/cell and lysed at 24, 48, and 72 h post-infection (hpi). Protein expression was analyzed by SDS–
PAGE and immunoblotting with antibodies to HPIV2 N, P and V proteins and cellular GAPDH, which serves as a loading control.
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nucleotide 1917, which changed the length of the poly(A) tract in the
gene-end signal from 7 to 6 residues. Mutations or natural variation
affecting the length of the poly(A) sequence of the gene-end signal are
common for paramyxoviruses in general and usually are without
phenotypic consequences (Collins and Crowe, 2007; Kolakofsky et al.,
1998; Rassa et al., 2000), and therefore mutant 1 was analyzed
further. Western blot analysis revealed that expression of the gene
downstream of the gene-end mutation, encoding P protein, is at least
equivalent to expression of P in rHPIV2-WT-infected cells (Fig. 1C). At
24, 48, and 72 h post-infection (hpi), both HPIV2 N and P proteins
were expressed efﬁciently by rHPIV2-Vko (Fig. 1C), indicating that the
mutation in the gene-end sequence of rHPIV2-Vko does not function-Table 1
Sequence analysis of recovered rHPIV2-Vko.
a Antigenomic sense nucleotide sequence of selected regions of HPIV2 genome.
b Adventitious mutations were frequently noted in the N gene-end sequence of recovere
c Sequence of the P editing site of recovered viruses compared to the HPIV2-Vko cDNA se
d The P editing site mutations to create HPIV2-Vko are indicated by bold type.
e Sequences of viruses recovered from HPIV2-Vko cDNA from ﬁve transfections. Underlin
f Recovered rHPIV2-Vko clone no. 1 is shaded to indicate that this virus was used for allally impair mRNA synthesis and can be considered an incidental
mutation of little biological signiﬁcance. rHPIV2-Vko replicated
efﬁciently in vitro, and sequence analysis of its entire genome showed
that it was free of any additional adventitiousmutations. Western blot
analysis of infected LLC-MK2 cell lysates using antibodies directed
against both the N- and C-termini of the HPIV2 V protein conﬁrmed
that rHPIV2-Vko did not express the V protein (Fig. 1C). In addition,
smaller bands were not detected in either rHPIV2-WT or rHPIV2-Vko
with antibodies speciﬁc to the N-terminus of P/V, while V and P were
readily detected, indicating that neither virus expresses a W protein
and that the alterations in the editing site prevent expression of C-
terminally truncated V or W proteins. Therefore, this isolate was used
throughout the remainder of the study as rHPIV2-Vko.d rHPIV2-Vko mutants. The gene-end sequence is boxed.
quence used for virus recovery.
ed nucleotides indicate adventitious mutations.
experiments in the study.
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Single and multi-cycle replication of rHPIV2-Vko was assessed in
A549, Vero, and LLC-MK2 cells infected at an MOI of 5.0 or 0.01
TCID50/cell, respectively (Fig. 2A and B). In A549 cells, a human type II
pneumocyte cell line, rHPIV2-Vko replicated poorly and reached a
peak titer of 3.0 log10TCID50/ml following high MOI inoculation, 100-
fold lower than the peak titer of rHPIV2-WT (peak titer 5.0
log10TCID50/ml). Similarly, rHPIV2-Vko reached a peak titer of 3.6
log10TCID50/ml following low MOI inoculation, 630-fold lower thanFig. 2. Comparison of the growth of rHPIV2-WT and rHPIV2-Vko in vitro in IFN-competent
replication of rHPIV2-WT (ﬁlled squares) or rHPIV2-Vko (open squares) in A549, Vero, or LLC
0.01 (B) TCID50/cell with each virus. Aliquots of culture media replaced at 24-h intervals wer
mean virus titer for each time point is expressed as log10TCID50/ml±SE. (C) Plaque size com
LLC-MK2 cells (right panels) were infected with the indicated viruses at anMOI of 0.01, 0.001
for 10 days p.i., then ﬁxed in methanol. Plaques were stained with polyclonal anti-HPIV2 rab
antibodies and peroxidase substrate. Plaques were imaged without magniﬁcation.the peak titer of rHPIV2-WT (peak titer 6.4 log10TCID50/ml).
Furthermore, titers of rHPIV2-Vko reached a plateau after 2 days
post-infection (p.i.), while titers of rHPIV2-WT increased through day
8 p.i. Replication of rHPIV2-Vko was also evaluated in twomonkey cell
lines (Fig. 2A and B). African green monkey Vero cells were selected
because they are unable to produce type I interferon (IFN) and
because they would be the substrate used to manufacture a live
attenuated HPIV2 vaccine. IFN-competent LLC-MK2 rhesus monkey
kidney cells were chosen because rHPIV2-WT replicates efﬁciently in
this cell line. rHPIV2-Vko replication was only slightly restricted(A549 and LLC-MK2) and IFN-lacking (Vero) cells. Single-cycle (A) or multi-cycle (B)
-MK2 cells. Triplicate cell cultures in 6-well plates were infected at an MOI of 5.0 (A) or
e titrated by 10-fold serial dilution on LLC-MK2 cells and scored by hemadsorption. The
parison between rHPIV2-WT and rHPIV2-Vko. Monolayers of Vero cells (left panels) or
, or 0.0001 TCID50/cell. Cells were overlaid with 0.8%methylcellulose, incubated at 32 °C
bit immune serum and developed with horseradish peroxidase-conjugated anti-rabbit
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Vero and LLC-MK2 cells compared with rHPIV2-WT following low
MOI inoculation (pb0.001, two-way ANOVA with Bonferroni post-
tests). In multi-cycle growth curves, replication of rHPIV2-Vko was
restricted 50-fold in Vero cells (peak titer 6.4 log10TCID50/ml) and
2500-fold in LLC-MK2 cells (peak titer 5.4 log10TCID50/ml) compared
with rHPIV2-WT (peak titer 8.1 log10TCID50/ml in Vero cells and 8.8
log10TCID50/ml in LLC-MK2 cells). Sequence analysis of rHPIV2-Vko
isolated from cell cultures after completion of the growth curves
conﬁrmed that the mutations introduced into the P/V editing site
remained intact. These data indicate that the growth of rHPIV2-Vko is
signiﬁcantly restricted in vitro, although to a lesser extent in the
absence of a cellular IFN response. The sensitivity of replication of
rHPIV2-Vko to elevated temperatures (37–40 °C)was also evaluated in
vitro to determine whether the V deletion altered the stability of the
replication complex. Replication at 37–39 °C was comparable to that
at 32 °C but was restricted N100-fold at 40 °C (data not shown),
indicating a temperature sensitivity of replication at or above 40 °C.
In order to assess the cell-to-cell spread of rHPIV2-Vko, we infected
monolayers of Vero and LLC-MK2 cells with serial dilutions of virus
using a methylcellulose overlay (Fig. 2C). Following incubation for 10
days, plaques were visualized by immunostaining with HPIV2-speciﬁc
antibodies, and plaque sizes were compared between rHPIV2-WT and
rHPIV2-Vko. In Vero cells, rHPIV2-Vko plaques were approximately
37% smaller than rHPIV2-WT plaques (2.4±0.2 pixels for rHPIV2-Vko
versus 3.8±0.2 for rHPIV2-WT, pb0.001). In LLC-MK2 cells, a more
dramatic reduction (94%) in the plaque size of rHPIV2-Vko was
observed compared with rHPIV2-WT (0.8±0.1 versus 13.5±1.0,
pb0.001). Thus, rHPIV2-Vko exhibits a small plaque phenotype that is
particularly pronounced in IFN-competent LLC-MK2 cells, but also is
apparent to a lesser extent in IFN-lacking Vero cells. Plaque size was
not assessed in A549 cells due to the overall poor multi-cycle
replication of rHPIV2-Vko in this cell line.
rHPIV2-Vko causes increased CPE compared to rHPIV2-WT
In the course of determining the replication kinetics of rHPIV2-Vko,
we observed that this mutant caused more syncytia formation and
CPE than rHPIV2-WT in LLC-MK2 and Vero cells. To further investigate
this phenomenon, LLC-MK2 cells were infected at high MOI (5.0
TCID50/cell), and CPE was inspected by microscopy. rHPIV2-Vko
caused extensive syncytia formation by 48 hpi, followed by CPE that
destroyed the infected cell monolayers by 72 hpi (Fig. 3A). In contrast,
rHPIV2-WT did not cause signiﬁcant CPE in any of the cell lines, and
syncytia did not form in LLC-MK2 cells until 7–8 days p.i. (Fig. 3A and
data not shown). CPE was not visible for either virus in A549 cells,
possibly due to the poor replication of rHPIV2-Vko in this cell line.
Recently, a mutant of HPIV1 that does not express the IFN
antagonist C proteins, rHPIV1-P(C−), was shown to cause extensive
CPE within a few days of infection in vitro, in contrast to the non-
cytopathic WT HPIV1, and this CPE was associated with extensive
apoptosis (Bartlett et al., 2008a). Since the V proteins of PIVs have
been reported to inhibit apoptosis (Sun et al., 2004; Wansley and
Parks, 2002) and since the CPE induced looked similar to that
observed for rHPIV1-P(C−), we next explored whether the CPE
induced by rHPIV2-Vko might also be due to apoptosis. In these
experiments, we used the HPIV1 viruses as positive (rHPIV1-P(C−))
or negative (WT HPIV1) controls for apoptosis. We determined the
frequency of apoptosis in infected cells using ﬂow cytometry to
detect activated caspase-3, the major effector caspase in the
apoptotic pathway. Replicate cultures of LLC-MK2 cells were infected
with rHPIV2-WT, rHPIV2-Vko, or the HPIV1 control viruses at an MOI
of 5.0 TCID50/cell and were ﬁxed at 24, 48, and 72 hpi. Cells were
then permeabilized and immunostained for activated caspase-3. As
described previously, rHPIV1-P(C−) was a potent inducer of
caspase-3 activation while rHPIV1-WT was not (Fig. 3B). Speciﬁcally,in cultures infected with rHPIV1-WT, less than 1.2% of the cells
expressed activated caspase-3 through 72 hpi, which was similar to
mock-infected cultures (approximately 0.5% positive for activated
caspase-3). In contrast, in cultures infected with the rHPIV1-P(C−)
positive control, greater than 50% of the cells at 48 and 72 hpi
expressed activated caspase-3, indicative of cells undergoing
apoptosis. rHPIV2-WT caused slightly more apoptosis than rHPIV1-
WT, with 7.1% of cells expressing activated caspase-3 at 72 hpi
(pb0.001). Unexpectedly, in rHPIV2-Vko-infected cultures, there was
only a small (2-fold) increase in activated caspase-3-positive cells
(14.2% at 72 hpi) compared to rHPIV2-WT. While this increase was
statistically signiﬁcant (pb0.001), we had expected a substantially
larger increase given the extent of cell destruction that was evident
from light microscopic evaluation (Fig. 3A). Extensive cell destruc-
tion also was evident from the decrease in the forward scatter
parameter for events measured by FACS analysis of rHPIV2-Vko-
infected cultures (Fig. 3B), which indicates reduced cell size and
accumulation of cell debris. These results suggested that the
majority of cells infected with rHPIV2-Vko were not dying through
an apoptotic pathway.
Because antibody against activated caspase-3 has the potential to
bind non-speciﬁcally to necrotic cells, leading to an overestimation of
the percent apoptotic cells, we conﬁrmed cleavage activation of
caspase-3 by immunoblot analysis of infected LLC-MK2 cell lysates
(Fig. 3C). As we observed by ﬂow cytometric detection of activated
caspase-3, the cleaved (activated) form of caspase-3 was detected by
immunoblot at 48 and 72 h after infection with rHPIV2-Vko or rHPIV1-
P(C−). Cleaved caspase-3 was also detected to a lesser extent in cells
infected with rHPIV2-WT, though not rHPIV1-WT, correlating with
results seen by ﬂow cytometry.
We next evaluated cytotoxicity by the quantiﬁcation of plasma
membrane damage. One ubiquitous intracellular enzyme that is
rapidly released into culturemedium only upon damage to the plasma
membrane is lactate dehydrogenase (LDH); therefore, measuring
activity of LDH released into the culture media allows rapid
quantiﬁcation of cells whose plasma membrane has been damaged
by cytotoxic effect. An increase in the level of LDH activity in the
culture media is proportional to the number of dead or damaged cells
in the culture. When we measured LDH release from LLC-MK2 cells at
24, 48, and 72 hpi, we found that rHPIV2-Vko induced approximately
40% more LDH release at 72 hpi than rHPIV2-WT or, surprisingly,
rHPIV1-P(C−) (Fig. 3D). We conclude from these data that rHPIV2-
Vko exhibits a marked increase in its ability to induce cell–cell fusion
and cytopathicity compared to rHPIV2-WT. However, unlike rHPIV1-P
(C−), rHPIV2-Vko appears to cause CPE primarily through syncytia
formation and necrosis rather than through the induction of
apoptosis, although both processes are active during infection with
rHPIV2-Vko.
One possible explanation for the early appearance (day 2) of
syncytia in rHPIV2-Vko-infected cells is that F and HN may
accumulate in the plasma membrane more rapidly than in rHPIV2-
WT-infected cells and enhance cell–cell fusion. To quantify expres-
sion of F and HN on the plasma membrane, we stained live adherent
LLC-MK2 cells for cell surface expression of HPIV2 F and HN and
estimated the level of expression by FACS analysis. We chose this
method because it would allow us to compare the relative amount of
F and HN glycoprotein incorporated into the infected cell mem-
branes without involuntarily analyzing intracellular F and HN. Using
this technique, no signiﬁcant difference in mean ﬂuorescence
intensity (MFI) was detected for F at 24 hpi (MFI of 60.3 for
rHPIV2-WT vs. 51.4 for rHPIV2-Vko) or 48 hpi (MFI of 87.0 for
rHPIV2-WT vs. 80.1 for rHPIV2-Vko). Similarly, the MFI for HN
protein was comparable between cells infected with either of the
two viruses at both 24 hpi (MFI of 357 for rHPIV2-WT vs. 338 for
rHPIV2-Vko) and 48 hpi (MFI of 363 for rHPIV2-WT vs. 405 for
rHPIV2-Vko). Since we were unable to detect a difference in cell
290 A. Schaap-Nutt et al. / Virology 397 (2010) 285–298surface glycoprotein expression, we conclude that factors in addition
to the level of F and HN expression likely play a major role in syncytia
formation. However, these data and interpretations are offered withthe caveat that infection with rHPIV2-Vko is a dynamic process where
some cells form syncytia and others detach or die, adding uncertainly
into the interpretation of the F and HN expression data.
Fig. 4. IFN induction and signaling in response to HPIV2 infection. (A) IFN-β induction during infection with rHPIV2-WT and rHPIV2-Vko. LLC-MK2 cells were infected with rHPIV2-
WT (ﬁlled boxes) or rHPIV2-Vko (open boxes) at an MOI of 5.0 TCID50/cell. The culture medium was replaced at 0, 24, 48, 72, and 96 hpi and aliquots were analyzed to determine
virus titer and ELISA IFN-β levels. Bar graphs show IFN-β concentrations (scale on right Y-axis), which were determined by comparison with an IFN-β standard curve and are
expressed in pg/ml±SE based on results for triplicate samples from two independent experiments. Asterisks indicate samples in which IFN-β levels were signiﬁcantly higher than in
rHPIV2-WT-infected culture supernatant at the same time point (pb0.001). The lower limit of detection was 12 pg/ml. Line graphs show the virus titer (scale on left Y-axis) for each
sample, determined by 10-fold serial dilution of the culture supernatant on LLC-MK2 cells. Mean daily virus titers are expressed as log10TCID50/ml±SE. (B) IRF-3 dimerization in
HPIV2-infected LLC-MK2 cells. Cells were mock-infected or infected with rHPIV2-WT or rHPIV2-Vko at an MOI of 5.0 TCID50/cell and lysed at 24 and 48 hpi. Cell lysates were resolved
by PAGE electrophoresis under native conditions, and immunoblot was used to identify both monomeric and dimeric forms of IRF-3. (C) Type I IFN signaling during infection with
rHPIV2-WT and rHPIV2-Vko. Vero cells in six-well plates were mock-infected or infected with rHPIV2-WT or rHPIV2-Vko at an MOI of 5.0 TCID50/cell for 24 h. Cells were then left
untreated or were treated with 100 or 1000 IU/ml IFN-β (2 cultures per treatment per virus). After 24 h, the cells were infected with VSV-GFP and incubated for 48 h. A
phosphorimager was used to visualize the VSV-GFP foci. The graph represents the percent inhibition of VSV-GFP foci (±SE) in IFN-β-treated versus untreated cells. (D) STAT2
protein degradation. Vero cells infected at anMOI of 5.0 TCID50/cell were lysed at 24 or 48 hpi and analyzed by SDS–PAGE and immunoblotted for STAT2, STAT1, and GAPDH (loading
control) cellular proteins and for P and V viral proteins.
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HPIV2 V protein has been shown to directly bind to the cytosolic
dsRNA sensor MDA5 and to inhibit production of IFN-β in response to
viral infection (Andrejeva et al., 2004; Childs et al., 2007). Although the
importance of MDA5 inhibition for sensing paramyxovirus infection has
not yet beenwell deﬁned,we sought to determine the effect of deletingV
protein on the ability of HPIV2 to block IFN-β induction during infection.
LLC-MK2cellswere infectedat anMOIof 5.0 TCID50/cellwith rHPIV2-WTFig. 3. Comparison of CPE, caspase-3 activation, and cytotoxicity induced by infection wit
infected or infected with rHPIV2-WT or rHPIV2-Vko at an MOI of 5.0 TCID50/cell. Syncyt
Photomicrographs taken at 72 hpi show increased CPE in rHPIV2-Vko-infected cultures. Moc
FACS analysis. LLC-MK2 cells were mock-infected or infected with the indicated viruses at an
positive controls. At 24, 48, and 72 hpi, cells were ﬁxed, permeabilized, and stained for ac
independent experiments. Gates indicate the population of cells (% of total events) posi
Immunoblot for caspase-3. LLC-MK2 cells infected at an MOI of 5.0 TCID50/cell were lysed at
length procaspase-3 is approximately 35 kDa and is proteolytically cleaved into activated
dehydrogenase (LDH) release from LLC-MK2 cells collected at 24, 48 and 72 hpi. LDH in the c
amicroplate reader; activity is expressed as absorbance at 490nm. Spontaneous (background
the maximal release of LDH activity was determined from supernatant of a lysed, mock-infor rHPIV2-Vko, and the concentration of IFN-β in the culture supernatant
was determined by an ELISA that detects active IFN-β (Fig. 4A). A low
level of IFN-β was detected in response to rHPIV2-WT infection of LLC-
MK2 cells (95 pg/ml at 72 hpi and 228 pg/ml at 96 hpi). In contrast, cells
infected with rHPIV2-Vko showed markedly increased IFN-β production
by 72 hpi (20-fold over rHPIV2-WT). Similar results were found using a
type I IFN bioassay based on the inhibition of plaque formation by VSV-
GFP (data not shown). Unlike rHPIV2-WT, rHPIV2-Vko appears to be
unable to inhibit the production of IFN-β by infected cells.h rHPIV2-WT or rHPIV2-Vko. (A) Conﬂuent monolayers of LLC-MK2 cells were mock-
ium formation and cell death are apparent by 48 h after infection with rHPIV2-Vko.
k cultures appeared like those of rHPIV2-WT. (B) Evaluation of caspase-3 activation by
MOI of 5.0 TCID50/cell, including rHPIV1-WT and rHPIV1-P(C−) viruses as negative and
tivated caspase-3. Dot plots are representative of data for triplicate samples from two
tive for activated caspase-3 at each time point as determined by FACS analysis. (C)
24, 48, or 72 hpi and then analyzed by SDS–PAGE and caspase-3 immunostaining. Full-
17 kDa and 12 kDa fragments. (D) Cytotoxicity was quantiﬁed by measuring lactate
ulture supernatant activated a colorimetric detection reagent, which was detected using
) LDH release was determined from culture supernatant frommock-infected cells, while
ected culture.
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transcription factor IRF-3, which is activated by phosphorylation,
causing it to dimerize and translocate to the nucleus where it binds to
the IFN-β promoter (Yoneyama et al., 1998). To evaluate the
dimerization of IRF-3 in response to HPIV2 infection, LLC-MK2 cells
were infected with rHPIV2-WT or rHPIV2-Vko at anMOI of 5.0 TCID50/
cell, and dimerization assays were performed at 24 and 48 hpi.
rHPIV2-WT inhibited IRF-3 dimerization, whereas rHPIV2-Vko in-
duced IRF-3 dimerization (Fig. 4B). No IRF-3 dimerization was evident
in mock-infected cells. Therefore, dimerization of IRF-3 following
rHPIV2-Vko infection correlates well with the high levels of IFN-β
production in response to this virus.
rHPIV2-Vko cannot block IFN signaling and does not target STAT2 for
degradation
HPIV2 V protein efﬁciently blocks type I IFN signaling following
infection by targeting STAT2 for proteasomal degradation (Andrejeva
et al., 2002; Nishio et al., 2002, 2005). Therefore, we determined
the effect of deleting the V protein on the ability of HPIV2 to block
type I IFN signaling using a biological assay that assesses the
establishment of an antiviral state in rHPIV2-infected cells. Vero
cells, which do not produce type I IFN, were mock-infected or
infected with rHPIV2s at an MOI of 5.0 TCID50/cell for 24 h prior to
treatment with IFN-β. Twenty-four hours after IFN-β treatment, cells
were infected with vesicular stomatitis virus expressing green
ﬂuorescent protein (VSV-GFP). The number of VSV-GFP plaques
was counted 48 h later, and the percent inhibition of plaque
formation due to IFN-β treatment was calculated relative to cells
that were not treated with IFN-β (Fig. 4C). In cells that were not
infected with HPIV2 (Mock), VSV-GFP replication was inhibited 80%
by IFN-β treatment (100 or 1000 IU/ml). The average size (area) of
the remaining plaques was reduced approximately 6-fold in IFN-
treated wells compared with the size of plaques in untreated wells.
In contrast, infection with rHPIV2-WT reduced the inhibitory effect
of IFN-β by 75%, i.e. to a level of 20%, indicating that rHPIV2-WT can
prevent IFN-β signaling and thereby blunt the induction of an
antiviral state. Infection with rHPIV2-Vko was unable to inhibit the
antiviral effect of IFN-β resulting in 80% inhibition of VSV-GFP
plaque formation in IFN-β-treated cells, identical to that in the
mock-infected cultures. The plaque formation by VSV-GFP in cells
infected with rHPIV2-Vko, even in the absence of IFN treatment, was
inhibited 70% (data not shown), for reasons that are undeﬁned but
likely involve the enhanced CPE observed with this virus. Thus, the
magnitude of IFN-mediated inhibition associated with this mutant
was calculated based on the reduced number of VSV-GFP plaques
that form on rHPIV2-Vko-infected monolayers in the absence of
added IFN-β.
To investigate whether rHPIV2-Vko was unable to block IFN
signaling because it lacked the ability to degrade STAT2, we examined
lysates from Vero cells infected with rHPIV2 at an MOI of 5.0 TCID50/
cell for the expression of STAT1 and STAT2 proteins (Fig. 4D). By 24
hpi, rHPIV2-WT had completely degraded STAT2 in the infected cells
and continued to prevent accumulation of STAT2 through 48 hpi.
rHPIV2-Vko-infected cells, however, expressed levels of STAT2 that
were as high or higher than in mock-infected cells through 48 hpi.
Although STAT2 was degraded by rHPIV2-WT and not by rHPIV2-Vko,
all infected cell lysates expressed equivalent amounts of STAT1. We
also observed that STAT1 could still be phosphorylated in response to
IFN-β when we stimulated cells infected with either rHPIV2-WT or
rHPIV2-Vko prior to lysis and performed immunoblots using anti-
bodies speciﬁc to the phosphorylated form of STAT1 (data not
shown). Therefore, rHPIV2-Vko appears to be unable to degrade
STAT2, eliminating its ability to block type I IFN signaling, whereas
neither rHPIV2-Vko nor rHPIV2-WT appeared to affect STAT1 stability
or phosphorylation.Attenuation of rHPIV2-Vko in vivo
To assess the ability of rHPIV2-Vko to replicate in vivo, we
inoculated African green monkeys (AGMs) intranasally (IN) and
intratracheally (IT) with 106 TCID50 of virus per site and determined
virus titers from nasopharyngeal swabs (representative of the URT)
and tracheal lavage samples (representative of the LRT) (Fig. 5A).
rHPIV2-WT replicated to a mean peak titer of 103.5 TCID50/ml in the
URT and approximately 104 TCID50/ml in the LRT. However, rHPIV2-
Vko was undetectable in all of the AGM respiratory tract samples. The
lower limit of detection was 0.5 log10 TCID50/ml. Likely as a result of
its poor replication, rHPIV2-Vko was also poorly immunogenic. While
infection of rHPIV2-WT caused a 4.2-fold rise in HPIV2 neutralizing
antibody titer in AGMs between day 0 and day 28 p.i., there was no
signiﬁcant rise in response to rHPIV2-Vko (1.5-fold). The poor growth
and lack of immunogenicity of rHPIV2-Vko in AGMs indicate that the V
protein is required for infection in vivo and suggest that a V-deletion
mutant would not make a successful vaccine candidate.
Restricted growth of rHPIV2-Vko in primary human airway epithelial
cells (HAE)
As V protein has been implicated in host range restriction of
paramyxovirus replication (Parisien et al., 2002; Park et al., 2003), we
wanted to determine if replication could be seen in primary epithelial
cell cultures of human origin. In vitro models of the human airway
epithelium (HAE) can be derived from primary human airway cells
grown at an air–liquid interface where they differentiate into a
multilayered, polarized epithelium. Unlike transformed monolayer
cell lines, these primary polarized epithelial cultures closely mimic
morphological and physiological characteristics of the human airway
epithelium in vivo, including mucus production and ciliary motion
(Matsui et al., 1998; Pickles et al., 1998). The HAE model has been
used to investigate characteristics of infection for a number of
respiratory viruses, including human coronaviruses, inﬂuenza A
virus, RSV, HPIV1 and HPIV3 (Bartlett et al., 2008b; Leonard et al.,
2008; Sims et al., 2005; Thompson et al., 2006; Zhang et al., 2005,
2002). In the present study, we found that, following apical
inoculation of HAE cells with an MOI of 0.01 TCID50/cell, rHPIV2-WT
replicated efﬁciently, reaching a peak titer of 104 TCID50/ml (Fig. 5B).
However, as in the AGM samples, rHPIV2-Vko was undetectable in the
HAE culture supernatant through day 7 p.i. and appears to be unable
to infect HAE productively (Fig. 5B). To determine whether a high
level of IFN production limited the growth of rHPIV2-Vko in HAE
cultures, we measured the concentration of IFN-β secretion by ELISA
(Fig. 5C). A low level of IFN-βwas detected in response to rHPIV2-WT
infection of HAE (peak of 94 pg/ml on day 4 p.i.). In contrast, cells
infected with rHPIV2-Vko showed very little secretion of IFN-β (b20
pg/ml), most likely due to the virus' severely restricted replication.
Discussion
Evaluation of mutants of the Toshiba strain of HPIV2, either
containing a deletion of the V-speciﬁc cysteine-rich domain, desig-
nated as rPIV2V(−) (Kawano et al., 2001), or encoding an alteration of
the P editing site that results in ablation of V expression, designated as
rPIV2/P-edit (Nishio et al., 2005), indicated that HPIV2 Vwas required
for efﬁcient replication, particularly in IFN-competent cells. We
sought to prepare and further characterize an independent Vko
HPIV2 to examine the effect of the deletion on the synthesis and
signaling of IFN, on cytopathology, and on replication both in vitro and
in vivo. To this end, rHPIV2-Vko was generated using a low passage
HPIV2 isolate that replicates efﬁciently in AGMs and that was
completely sequenced to conﬁrm its sequence comparability to the
WT virus from which it was derived. Since deletion of IFN antagonists
such as the NS1/NS2 proteins of inﬂuenza virus (Ferko et al., 2004;
Fig. 5. Restriction of rHPIV2-Vko replication in African green monkeys and an in vitro model of human airway epithelium. (A) Replication in the upper (URT) and lower (LRT)
respiratory tract of African green monkeys. Groups of AGMs were inoculated intranasally and intratracheally with 106 TCID50 of rHPIV2-WT (n=21) or rHPIV2-Vko (n=4). Mean
daily virus titers±SE in nasopharyngeal swabs (representative of the URT) and tracheal lavage ﬂuid (representative of the LRT) were determined at each indicated sampling day. The
limit of detection was 0.5 log10 TCID50/ml. (B) Primary polarized human airway epithelial (HAE) tissue cultures, which closely modeled authentic airway epithelium, were infected
at the apical surface with rHPIV2-WT or rHPIV2-Vko at lowMOI (0.01 TCID50/cell). Virus shed into the apical compartment was determined on days 0 to 7 p.i. Virus titers shown are
the means of duplicate cultures from two donors±SE. The limit of detection is 1.2 log10TCID50/ml. (C) IFN-β induction during infection of HAE. Apical wash ﬂuid was analyzed to
determine ELISA IFN-β levels, which were determined by comparison with an IFN-β standard curve. IFN-β levels are expressed in pg/ml±SE based on duplicate samples from two
donors; the lower limit of detection was 12 pg/ml.
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(Teng et al., 2000; Whitehead et al., 1999; Wright et al., 2006) can
attenuate viruses in vivo and have potential for use as live attenuated
virus vaccines, we were particularly interested to see if rHPIV2-Vko
had properties suitable for such a vaccine.
rHPIV2-Vko was impaired in replication in vitro, as indicated both
by a low frequency of recovery of infectious virus from cDNA and by a
considerable restriction of replication in vitro, particularly in IFN-
competent LLC-MK2 and A549 cells. rHPIV2-Vko replication in Vero
cells, a cell line unable to produce type I IFN (Emeny and Morgan,
1979; Mosca and Pitha, 1986; Wathelet et al., 1992) and also low in
constitutive expression of IRF3 (Chew et al., 2009), was 10-fold
restricted in peak titer during multi-cycle replication compared to
rHPIV2-WT, whereas the previously described rPIV2/P-edit was
restricted over 10,000-fold in the same cell line (Nishio et al., 2005).
The reason for this difference in replication between the two
constructs of rHPIV2-Vko was not deﬁned. It is noteworthy that, in
the present study, the entire sequence of the rHPIV2-Vko mutant was
analyzed, identifying only a single adventitious mutation. This
involved a substitution in the N gene-end signal that changed the
length of the poly(A) segment from 7 to 6 residues, a type of change
that is common in paramyxoviruses and is usually innocuous (Collins
and Crowe, 2007; Kolakofsky et al., 1998; Rassa et al., 2000). This
mutation does not alter the length of the untranslated region, and
other variable gene-end poly(A) tracts have been demonstrated to befunctionally equivalent in directing polyadenylation (Rassa et al.,
2000). This virus was largely replication competent and did not
reduce the expression of the N and P proteins, suggesting that this
single adventitious mutation was inconsequential and that rHPIV2-
Vko was a clean V-deletion mutant. It should be noted that there may
be increased expression of P protein due to the elimination of RNA
editing. This method of ablating V expression removes the possibility
of generating a truncated V orW protein but introduces the possibility
that greater P expression may also have contributed to the reduction
in rHPIV2-Vko replication.
The 10-fold reduction in replication and the reduced plaque size of
rHPIV2-Vko versus rHPIV2-WT in Vero cells identiﬁed a modest IFN-
independent role of V in supporting replication in vitro. A role for V in
replication in vitro has been seen with other rubulaviruses and could
be due to a recently reported function of V in promoting virus growth
through an interaction with the L polymerase (Nishio et al., 2008). A
C-terminal truncation mutant of the PIV5 V protein was restricted in
replication in IFN-competent cells but grew as efﬁciently as PIV5 WT
in Vero cells, while a PIV5 deletionmutant lacking the entire V protein
could not be recovered at all (He et al., 2002). In IFN-competent cells,
however, all of the reported rubulavirus V knockout and truncation
mutants grow poorly and form pinpoint plaques (He et al., 2002). The
severe restriction of replication seen with rubulavirus V knockout and
V truncationmutants in IFN-competent cells is not seenwith similar V
mutants derived from viruses of other paramyxovirus genera
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respirovirus Sendai virus (SeV), for example, grows efﬁciently in IFN-
competent cells without V protein, suggesting that V is less crucial for
replication of respiroviruses than for rubulaviruses (Delenda et al.,
1997; Kato et al., 1997a). This likely is because these other genera also
possess the accessory C protein, which is not found in rubulaviruses;
the functions of the rubulavirus V protein are distributed between the
V and C proteins of these other genera. Taken together, these data
point toward a role of both IFN-dependent and IFN-independent
functions of V in enabling virus replication in vitro.
rHPIV2-Vko-infected cells produced IFN-β efﬁciently whereas
rHPIV2-WT did not, clearly indicating that rHPIV2 V protein inhibits
the induction of IFN. All of the paramyxovirus V proteins examined to
date have been shown to down-regulate IFN-β induction using a
mechanism linked to interaction of the C-terminus of V protein with
the helicase domain of MDA5 to block its activation and signaling to
IRF3 (Andrejeva et al., 2004; Berghall et al., 2006; Childs et al., 2007,
2009). Although several studies have indicated that RIG-I is the
primary helicase for sensing paramyxoviruses rather than MDA5
(Kato et al., 2005, 2006; Loo et al., 2008), the conservation of the V–
MDA5 interaction across the four above-mentioned paramyxovirus
genera signiﬁes that its role is likely important.Why RIG-I, which does
not seem to be a target of paramyxovirus V proteins (Childs et al.,
2007; Yoneyama et al., 2005), apparently does not function efﬁciently
in cells infected with rubulaviruses to produce activated IRF3/7 and
induce IFN-β remains undeﬁned.
rHPIV2-WT also inhibited the signaling of IFN-β by efﬁciently
degrading STAT2 whereas rHPIV2-Vko did not, conﬁrming previous
observations that HPIV2 modulates IFN signaling in human and
monkey cells by proteasomal degradation of STAT2 rather than STAT1,
which is targeted by rubulaviruses PIV5, SV41 and MuV (Andrejeva et
al., 2002; Didcock et al., 1999a, 1999b; Nishio et al., 2005, 2001;
Parisien et al., 2001; Precious et al., 2005; Ulane and Horvath, 2002;
Ulane et al., 2005; Young et al., 2000). Our demonstration that rHPIV2-
WT can degrade STAT2 and block the antiviral effects of IFN-β in AGM-
derived Vero cells, while rHPIV2-Vko cannot, supports the use of AGMs
as a suitable in vivo model to examine the effect of V on replication in
vivo, likely reﬂecting the observation that human and monkey STAT1
and STAT2 proteins are highly conserved, sharing 99.3% and 97.8%
amino acid identity, respectively, between species (Nishio et al.,
2005).
rHPIV2-Vko infection induced extensive CPE in vitro whereas
rHPIV2-WT was largely non-cytopathic until very late in infection.
Several diverse and complex pathways can lead to PIV-induced
apoptosis, and V can play a role in preventing apoptosis of infected
cells (He et al., 2002; Lei et al., 2009; Peters et al., 2008; Sun et al.,
2004; Wansley and Parks, 2002). PIV5 and SeV V mutant viruses, like
rHPIV2-Vko, were more cytopathic than their respective WT viruses
(Capraro et al., 2008; Kato et al., 1997a). The HPIV2 V truncation
mutant induced more cell death in Vero cells than HPIV2-WT
(Kawano et al., 2001). In the present study, the mechanism of cell
death for rHPIV2-Vko-infected cells was characterized, and the
ﬁndings indicate that the CPE did not appear to be solely apoptotic
in nature. We observed signiﬁcantly more syncytia formation upon
infection with rHPIV2-Vko than with rHPIV2-WT beginning at very
early times in infection. Since our rHPIV2-WT and the rHPIV2-Vko
mutant are identical in protein sequence except for the V deletion, the
difference in syncytia phenotype was not due to differences in
sequence of F or HN although changes in F or HN clearly can alter this
phenotype (Tsurudome et al., 2008; Yuasa et al., 1995). rHPIV2-Vko
exhibited greater necrosis than rHPIV2-WT-infected cells and induced
a low level of apoptosis, but the relationship between syncytia
formation and necrosis was not further deﬁned. Thus, apoptosis, cell
necrosis, and syncytia formation contributed to the enhanced CPE
seen with rHPIV2-Vko infection, with necrosis appearing to be a
greater contributor than apoptosis.rHPIV2-Vko was not recovered from the URT and LRT of AGMs,
indicating that the V protein is required for detectable replication of
HPIV2 in vivo in non-human primates. To address whether this
restriction of replication was speciﬁc to the organized epithelium of
monkeys, i.e., a host range effect that could be speciﬁed by the V protein
(Parisien et al., 2002; Park et al., 2003), the replication of rHPIV2-Vkowas
also examined in human organized epithelial cultures. Replication was
not seen in the human organized epithelial cells, conﬁrming that HPIV2
V has a profound effect on replication in both human and monkey
organized epithelia. The ability of V mutant viruses to exhibit
attenuation in vivo has been seen with other paramyxoviruses. A V
mutant of PIV5 was restricted in replication in ferrets but not mice, a
clear host range difference (Capraro et al., 2008). A measles virus Vko
mutantwasattenuated in rhesusmonkeys, as assessedby the absenceof
clinical illness and a reduction in themagnitude and duration of viremia
(Devaux et al., 2008). Similarly, V protein defective canine distemper
virus was restricted 50- to 100-fold in replication in ferrets (von
Messling et al., 2006). SeV V mutants that replicated efﬁciently in vitro
were signiﬁcantly attenuated in mice with a shorter duration of
replication and approximately 10-fold lower peak titers than WT SeV
(Kato et al., 1997a, 1997b). The greater restriction of rHPIV2-Vko in vivo
thanmorbillivirus or SeV Vmutants perhaps is due to V's role as the sole
IFN antagonist in HPIV2, whereas measles and SeV have both V and C
proteins contributing to IFN antagonism.
The inability of rHPIV2-Vko to replicate to detectable titer in non-
human primates and in HAE suggests that this mutant would not be a
suitable candidate for development of a live attenuated HPIV2 vaccine,
i.e., it is over-attenuated in vivo. Development of a live attenuated
HPIV2 vaccine based on loss of the V protein IFN antagonist functions
would require that putative IFN antagonist domains in V be altered
selectively and that the domains responsible for the protein's functions
in genome replication, viral ﬁtness, and virus assembly be deﬁned and
remain unaltered in vaccine viruses. We are currently constructing
rHPIV2mutant viruses in which the V and P genes are expressed from
separate genes permitting the introduction of mutations in V without
affecting P. Only then can the contribution of each individual function
of V to attenuation and immunogenicity be assessed and appropriately
utilized in HPIV2 vaccine development. Clearly, the loss of all V
functions over-attenuates HPIV2 in vivo.
Materials and methods
Cell lines and viruses
Human HEp-2 (ATCC CCL 23) and rhesus monkey LLC-MK2 (ATCC
CCL 7.1) cells were maintained in OptiMEM I (Invitrogen, Grand
Island, NY) supplemented with 5% FBS and 50 μg/ml gentamicin
sulfate. African green monkey Vero cells (ATCC CCL-81) were
maintained in MEM (Gibco-Invitrogen) supplemented with 10% FBS,
50 μg/ml gentamicin sulfate and 4 mM L-glutamine. Human A549
cells (ATCC CCL-185) were maintained in F-12 nutrient mixture
(Gibco-Invitrogen) supplemented with 10% FBS, 50 μg/ml gentamicin
sulfate and 2 mM L-glutamine.
HAE cells were isolated from airway specimens of patients without
underlying lung disease. Tissues were provided by the National
Disease Research Interchange (NDRI, Philadelphia, PA) or by the UNC
Cystic Fibrosis Center Tissue Culture Core as excess tissue following
lung transplantation according to protocols approved by the Univer-
sity of North Carolina at Chapel Hill Institutional Review Board.
Primary cells derived from single patient sources were ﬁrst expanded
on plastic and then plated on collagen-coated, permeable Transwell-
COL (12-mm diameter) supports at a density of 3×105 cells per well.
HAE cultures were grown in custom media with provision of an air–
liquid interface for 4 to 6 weeks to form differentiated, polarized
cultures that resemble in vivo pseudostratiﬁed mucociliary epitheli-
um, as previously described (Pickles et al., 1998).
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the biologically derived HPIV2 strain V9412-6 (V94), which was
isolated from a nasal wash specimen from an infected infant and
was kindly provided by Dr. Peter Wright of Vanderbilt University
(Skiadopoulos et al., 2003). The sequence for the V94 strain was
determined previously (Genbank accession AF533010). The recom-
binant wild-type virus, rHPIV2-WT, was previously referred to as
rV94(15T) and was derived from an antigenomic cDNA copy of the
HPIV2 V94 genome (Nolan et al., 2007). rHPIV2-WT contains a
phenotypically silent NotI restriction site, which was introduced in
the upstream non-translated region of the N gene (HPIV2 nucleotide
positions 149–156), and a silent C to T substitution at position 6265
in the coding region of the F gene, as described previously (Nolan et
al., 2005; Skiadopoulos et al., 2003). Recombinant vesicular
stomatitis virus expressing green ﬂuorescent protein (VSV-GFP)
was kindly supplied by John Hiscott (Stojdl et al., 2003) and was
propagated in Vero cells.
Plasmid construction
A recombinant HPIV2 virus expressing only P protein from the P/V
gene (rHPIV2-Vko) was created by site-directed PCR mutagenesis
using the Advantage-HF PCR kit (Clontech Laboratories, Palo Alto, CA).
Four unique, silent restriction enzyme sites were inserted into the
rHPIV2-WT antigenomic sense cDNA to facilitate incorporation of a P
gene containing a mutated editing site: an AscI site at nucleotides
1986–1993 (GCCACACA to GGCGCGCC), BstEII and AgeI sites at
nucleotides 3188–3197 (GGTGCAATCA to GGTTACCGGT), and a SacII
site at nucleotides 3221–3226 (CCGATC to CCGCGG). Virus recovered
by reverse genetics from a plasmid containing these new restriction
enzyme sites grew equivalently to rHPIV2-WT in cell culture (data not
shown). PCR mutagenesis was then used to modify the RNA editing
site from AGGGGGGGAG to AGAGGAGGTGAG (changes underlined)
by (i) adding two G residues to shift the reading frame to encode P and
(ii) changing three of the seven consecutive G residues to prevent
further editing. All mutations were silent in the P ORF. In addition,
four nucleotides (TGAC) were inserted in noncoding sequence before
the BstEII/AgeI sites to correct for the “rule of six” (Skiadopoulos et al.,
2003). All regions of the mutated cDNAs that had been subjected to in
vitro polymerase reactions were sequenced using a Perkin-Elmer ABI
3730 sequencer with the BigDye sequencing kit v1.1 (Perkin-Elmer
AppliedBiosystems,Warrington,UK) aspreviously described (Newman
et al., 2004).
Virus recovery and propagation
rHPIV2-Vko was recovered by reverse genetics in HEp-2 cells and
propagated in LLC-MK2 cells as described previously (Nolan et al.,
2005; Skiadopoulos et al., 2003). rHPIV2-Vko was biologically cloned
by serial terminal dilution on LLC-MK2 cells. To conﬁrm that
recovered recombinant viruses contained the introduced mutations,
viral RNA was ampliﬁed by RT-PCR using the SuperScript First-Strand
Synthesis System (Invitrogen) and Advantage-HF PCR kit (Clontech),
and its sequence was determined in its entirety as previously
described (Newman et al., 2002; Skiadopoulos et al., 2003). Control
RT-PCR reactions in which the RT was omitted did not yield ampliﬁed
product, conﬁrming that the sequence represented viral RNA.
Puriﬁed virus stocks were obtained by infection of LLC-MK2 or
Vero cells, followed by centrifugation and banding of culture
supernatant containing virus in discontinuous 30%/60% (wt/vol)
sucrose gradients to minimize contamination by cellular factors such
as IFN. Virus titers were determined at 32 °C by serial dilution on LLC-
MK2 cells in 96-well plates using hemadsorption with guinea pig
erythrocytes to detect infected cultures (Hall et al., 1992; Skiadopou-
los et al., 2003). Titers are expressed as log10 TCID50/ml (50% tissue
culture infectious dose/ml).Immunoblot analysis of protein expression
Whole cell lysates were prepared by lysing cells (uninfected or at
24, 48, or 72 hpi) in radioimmunoprecipitation assay (RIPA) buffer
containing 50 mM Tris (pH 8), 150 mM NaCl, 1% IGEPAL CA-360
(Sigma-Aldrich, St. Louis, MO), 0.1% sodium dodecyl sulfate (SDS)
(Open Biosystems, Huntsville, AL), 0.5% deoxycholic acid (Sigma-
Aldrich), 50 mM NaF, 1 mM Na3VO4, and Complete Mini protease
inhibitor tablet (Roche, Indianapolis, IN). Lysates were heated to 70 °C
for 10 minutes in 1× NuPAGE LDS sample-loading buffer (Invitrogen)
and separated by SDS–polyacrylamide gel electrophoresis (SDS–
PAGE) in NuPAGE 4–12% or 10% Bis–Tris gels under denaturing and
reducing conditions (Invitrogen). For Native-PAGE analysis of IRF-3
monomers and dimmers, LLC-MK2 cells were lysed in buffer
containing 50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1% IGEPAL CA-
360 (Sigma-Aldrich), 50 mM NaF, 5 mM Na3VO4, and Complete Mini
protease inhibitor tablet (Roche). Native-PAGE was performed using
7% polyacrylamide gels and Tris–glycine running buffer (Bio-Rad,
Hercules, CA) containing 0.2% sodium deoxycholate in the cathode
chamber (Van Cleve et al., 2006). Gels were ﬁrst pre-run for 30 min at
40 mA prior to electrophoresis of lysates at 25 mA.
For immunoblotting, proteins were transferred to an Invitrolon
PVDF membrane (Invitrogen), blocked in phosphate-buffered saline
(PBS) containing 0.1% Tween and 5%milk powder, and incubated with
primary antibodies as indicated. Primary antibodies used for immu-
noblotting were mouse anti-GAPDH-peroxidase (GAPDH-71.1;
Sigma-Aldrich), rabbit anti-IRF-3 (FL-425; Santa Cruz Biotechnology,
Santa Cruz, CA), rabbit anti-STAT1 (E-23; Santa Cruz Biotechnology),
rabbit anti-STAT2 (C-20; Santa Cruz Biotechnology), rabbit anti-
phospho(Tyr701)-STAT1 (Chemicon/Millipore, Billerica, MA), and
rabbit anti-caspase-3 (Cell Signaling Technology, Danvers, MA).
Mouse antibodies to the amino-terminal P/V common region (85A)
(Tsurudome et al., 1989) and to the C-terminal V unique region (53-
1V) (Nishio et al., 1999) were described previously. A rabbit
polyclonal antiserum raised against a synthetic peptide from the
HPIV2 N protein amino acids 513–529 (CHEQYRGSQDDDANDATD)
was generated by Spring Valley Laboratories, Inc. (Woodbine, MD).
Proteins were detected by incubating membranes with horseradish
peroxidase-conjugated goat anti-rabbit or goat anti-mouse IgG (KPL,
Gaithersburg, MD) and visualized using SuperSignal West Pico
Chemiluminescent Substrate (Pierce, Rockford, IL).
Kinetics of rHPIV2-Vko replication
Conﬂuent monolayer cultures of A549, Vero, or LLC-MK2 cells in 6-
well plates were infected in triplicate at a multiplicity of infection
(MOI) of either 0.01 or 5.0 TCID50/cell, as indicated. After incubating
for 1 h with virus, cultures were washed three times and incubated at
32 °C. Medium from each well was harvested and replaced with fresh
medium at 24 h intervals. Virus present in each sample was quantiﬁed
by titration on LLC-MK2 cells and detected by hemadsorption. The
level of temperature sensitivity of replication was determined by
comparing level of rHPIV2-Vko replication to that of rHPIV2-WT at the
permissive temperature of 32 °C and at elevated temperatures of
37 °C, 38 °C, 39 °C, and 40 °C as previously described (Nolan et al.,
2007; Skiadopoulos et al., 1999).
Plaque size assay
Evaluation of plaque size was performed on Vero or LLC-MK2 cell
monolayers incubated at 32 °C. Infected cultures were covered with
0.8% methylcellulose overlay. Ten days p.i., the infected cultures were
ﬁxed with 80% methanol, and viral plaques were immunostained
using rabbit antiserum raised against puriﬁed HPIV2 virus (Spring
Valley Laboratories, Inc.) and a goat anti-rabbit secondary antibody
conjugated to horseradish peroxidase (KPL). The plaques were
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size was measured using Adobe Photoshop CS4 software. Mean
plaque sizes (in pixels±standard error, SE) are based on 30 plaques
per virus.
Flow cytometry
For detection of caspase-3 activation, LLC-MK2 cells were
harvested by scraping at 24, 48, and 72 h after infection with rHPIV2s
at an MOI of 5.0 TCID50/cell. Cells were washed with PBS, then ﬁxed
and permeabilized in BD Cytoﬁx/Cytoperm solution (BD Biosciences,
San Diego, CA). After washing in BD Perm/Wash buffer, cells were
stained with ﬂuorescein isothiocyanate (FITC)-conjugated monoclo-
nal rabbit anti-active caspase-3 antibody according to the manufac-
turer's protocol (FITC Active Caspase-3 Apoptosis kit, BD Biosciences).
For detection of cell surface expression of HN and F proteins, LLC-
MK2 cells were harvested by trypsinizing at 24 and 48 h after infection
with rHPIV2s at anMOI of 5.0 TCID50/cell. Cells were washedwith PBS
and stained with HPIV2-speciﬁc antibodies diluted in FACS buffer
(PBS, 2% FBS): mouse anti-HN IgG1 (42S1) and mouse anti-F IgG2a
(144-1A) (Tsurudome et al., 1989) followed by secondary antibodies
anti-mouse IgG1-AlexaFluor 647 and anti-mouse IgG2a AlexaFluor
488 (Invitrogen Molecular Probes). Stained cells were ﬁxed in FACS
buffer plus 2% paraformaldehyde prior to analysis. Sample analysis
was performed on a FACSCalibur (BD Biosciences) using CellQuestPro
software; further analysis was performed using FlowJo software
(TreeStar, Inc., Ashland, OR).
Cellular cytotoxicity
Cellular toxicity due to HPIV infection was determined by
measuring the amount of lactate dehydrogenase (LDH) leakage into
the cell culture media. Media were collected from HPIV-infected LLC-
MK2 cell cultures and centrifuged immediately after collection to
eliminate cells and cell debris. LDH release was quantiﬁed in the
supernatants using the Cytotoxicity Detection KitPLUS (LDH) (Roche)
according to the manufacturer's directions. The maximum LDH
release (100% cell lysis control) was determined by adding Lysis
reagent (Roche) to mock-infected cultures prior to supernatant
collection and centrifugation; background LDH release was deter-
mined from mock-infected cultures that were not lysed. LDH activity
upon reaction with a colorimetric reagent was measured using a
microplate reader (VMax, Molecular Devices, Sunnyvale, CA).
IFN-β ELISA
Culture supernatant from LLC-MK2 cells and apical wash ﬂuid
from HAE cultures were analyzed for IFN-β levels using the Human
Interferon-β ELISA Kit according to the manufacturer's protocol
(Fujirebio Inc., Tokyo, Japan). This ELISA kit speciﬁcally recognizes
the biologically active form of human IFN-β. Absorbance was
measured using a microplate reader (VMax, Molecular Devices) and
compared to a known concentration of IFN-β standard. IFN concen-
trations are expressed as means (pg/ml)±SE. IFN-β ELISA results
were veriﬁed using a type I IFN bioassay based on the inhibition of
VSV-GFP replication, as previously described (Bartlett et al., 2008b;
Park et al., 2003).
Type I IFN signaling assay
Vero cells were mock- or rHPIV2-infected at an MOI of 5.0 TCID50/
cell for 24 h. Cells were then left untreated or treatedwith 100 or 1000
IU/ml IFN-β (Avonex; Biogen Inc., Cambridge, MA) for 24 h prior to
infection with VSV-GFP. VSV-GFP-infected cells were cultured under
0.8% methylcellulose overlay prepared in MEM and supplemented
with 50 μg/ml gentamicin sulfate and 4 mM L-glutamine. Plates wereread for GFP expression 48 h after VSV-GFP infection using a Typhoon
8600 scanner (Molecular Dynamics), and the number of VSV-GFP-
positive foci was counted (Van Cleve et al., 2006).
Evaluation of virus replication in non-human primates
HPIV2-seronegative African green monkeys (AGMs) were inocu-
lated both intranasally (IN) and intratracheally (IT) with 1 ml of L-15
media containing 106.0 TCID50 of rHPIV2 per site. Nasopharyngeal
(NP) swabs were collected on days 0–10 p.i., and tracheal lavage (TL)
samples were collected on days 2, 4, 6, 8, and 10 p.i. Virus titers were
determined by serial dilution of the samples on LLC-MK2 cells as
described above and are expressed as log10 TCID50/ml. The lower limit
of detection was 0.5 log10 TCID50/ml.
Antibody response to HPIV2 was determined by 60% plaque
reduction neutralization titer (PRNT60) assay on LLC-MK2 cell
monolayers for serum samples collected from AGMs on study days
0 and 28 p.i. Test sera were heat inactivated (56 °C for 30 min), and
serial 4-fold dilutions beginning at 1:5 were made in OptiMEM
supplemented with 5% FBS. rHPIV2-WT, diluted to 103.5 TCID50/ml,
was added to the diluted serum and incubated at 32 °C for 1 h. Virus/
Serum mixtures were then added to LLC-MK2 cell monolayers in 24-
well plates, rocked for 1 h, and overlaid with 1% methylcellulose in
OptiMEM. After incubation at 32 °C for 6 days, cells were ﬁxed in
methanol:acetone (50/50) and immunostained using rabbit anti-
HPIV2 antiserum and goat anti-rabbit secondary antibody conjugated
to horseradish peroxidase (KPL). Plaques were visualized using
TrueBlue Peroxidase substrate (KPL).
Virus inoculation of HAE
Prior to inoculation with rHPIV2, the apical surfaces of HAE were
rinsedwith PBS to remove apical surface secretions and freshmedium
was supplied to the basolateral compartments. HAE cultures were
inoculated with rHPIV2s at low MOI (0.01 TCID50/cell) in 200-μl
inocula applied to the apical surface, and the cultures were incubated
at 37 °C for 2 h. The apical surfaces of the cultures were then rinsed
3×5 min with PBS and returned to the 37 °C incubator. Apical wash
samples were collected on days 0–7 p.i. after incubating the apical
surface with 400 μl media for 30 min at 37 °C. The apical wash media
were recovered and stored at−80 °C until virus titer was determined
as described above.
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